SEC Form 4 · accession 0001179110-18-006568
MOMENTA PHARMACEUTICALS INC · MNTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Young Kwon
Officer — SVP, Corporate Development
Period of report
May 8, 2018
Accepted (ET)
May 10, 2018 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235010
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 8, 2018 | M | 1,409 | $0.00 | A | 143,320 | D | |
| Common Stock | May 8, 2018 | S | 493 | $18.08 | D | 142,827 | D | |
| Common Stock | May 9, 2018 | M | 5,000 | $13.26 | A | 147,827 | D | |
| Common Stock | May 9, 2018 | S | 5,000 | $21.90 | D | 142,827 | D | |
| Common Stock | May 9, 2018 | M | 2,000 | $15.44 | A | 144,827 | D | |
| Common Stock | May 9, 2018 | S | 2,000 | $21.90 | D | 142,827 | D | |
| Common Stock | May 9, 2018 | M | 2,000 | $12.58 | A | 144,827 | D | |
| Common Stock | May 9, 2018 | S | 2,000 | $21.90 | D | 142,827 | D | |
| Common Stock | May 9, 2018 | M | 3,000 | $17.96 | A | 145,827 | D | |
| Common Stock | May 9, 2018 | S | 3,000 | $21.90 | D | 142,827 | D | |
| Common Stock | May 9, 2018 | M | 2,000 | $13.02 | A | 144,827 | D | |
| Common Stock | May 9, 2018 | S | 2,000 | $21.90 | D | 142,827 | D | |
| Common Stock | May 9, 2018 | S | 296 | $21.90 | D | 142,531 | D | |
| Common Stock | May 9, 2018 | S | 204 | $21.90 | D | 142,327 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | May 8, 2018 | M | 1,409 | D | — | — | Common Stock | 1,409 | 15,504 | D |
| Stock Option(Right to Buy) | $13.26 | May 9, 2018 | M | 5,000 | D | Feb 22, 2015 | Feb 22, 2021 | Common Stock | 5,000 | 52,000 | D |
| Stock Option(Right to Buy) | $15.44 | May 9, 2018 | M | 2,000 | D | Feb 14, 2016 | Feb 14, 2022 | Common Stock | 2,000 | 26,000 | D |
| Stock Option(Right to Buy) | $12.58 | May 9, 2018 | M | 2,000 | D | Feb 19, 2017 | Feb 19, 2023 | Common Stock | 2,000 | 26,800 | D |
| Stock Option(Right to Buy) | $17.96 | May 9, 2018 | M | 3,000 | D | Feb 18, 2018 | Feb 18, 2024 | Common Stock | 3,000 | 31,986 | D |
| Stock Option(Right to Buy) | $13.02 | May 9, 2018 | M | 2,000 | D | Feb 18, 2018 | Feb 18, 2025 | Common Stock | 2,000 | 33,725 | D |
Explanation of responses
- F1Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017.
- F2This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F3Restricted Stock Units convert into common stock on a one-for-one basis.
- F4Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.